Alnylam Pharma (ALNY) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of $30.93B. The enterprise value is $30.43B.

Alnylam Pharma has 130.07M shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is -4.15 and return on invested capital (ROIC) is -8.88%.

The current PE Ratio of Alnylam Pharma is -108.78. Alnylam Pharma’s PEG ratio is 2.82.

In the last 12 months, Alnylam Pharma had revenue of $2.25B and earned -$278.16M in profits. Earnings per share was -$2.17.

In the last 12 months, operating cash flow was -$8.31M and capital expenditures -$34.28M, giving a free cash flow of -$42.59M billion.

Alnylam Pharma pays an annual dividend of , resulting in a dividend yield of

Alnylam Pharma upcoming earnings date is May 1, 2025, Before Open.

Alnylam Pharma as a current ratio of 2.78, with Debt / Equity ratio of 19.32

In the past 12 months, Alnylam Pharma has paid -$99.22M in taxes.

Alnylam Pharma EV to EBITDA ratio is -175.72, with an EV/FCF ratio of -737.92.

Alnylam Pharma has $2.69B in cash and marketable securities with $1.30B in debt, giving a net cash position of -$1.40B billion.

Gross margin is 85.62%, with operating margin of -7.87%, and net profit margin of -12.37%.

The average price target for Alnylam Pharma is $322.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy